



BC Centre for Disease Control
An agency of the Provincial Health Services Authority

Date: September 21, 2011

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Influenza Vaccine for the 2011-2012 Season

The influenza vaccines approved in Canada for the 2011-2012 season will contain: an A/California/7/2009 (H1N1) – like virus, an A/Perth/16/2009 (H3N2)-like virus), and a B/Brisbane/60/2008-like virus (B Victoria lineage).

Three influenza vaccines will be supplied to British Columbia for the upcoming public campaign: FLUVIRAL® (GlaxoSmithKline), AGRIFLU® (Novartis), and FLUAD® (Novartis). Vaccine allocation has been determined by the provincial Health Authorities.

Please note the following changes to the Communicable Disease Control manual, Chapter 2- Immunization Program, Section VII, Biological Products”:

Influenza pages:

- Eligibility: vaccine for aboriginal peoples (on and off reserve) was introduced last season, and has been extended for the 2011-2012 season.
- The trivalent influenza vaccine dosage for infants 6 – 35months of age is 0.5 mL, one or two doses depending on whether a dose has been received in a previous year.
- Mild egg allergy is not a contraindication to trivalent influenza vaccine; individuals with mild egg allergy manifest only as hives can safely receive vaccine.

Administrative Circular 2011:10

IMMUNIZATION PROGRAMS AND VACCINE PREVENTABLE DISEASES SERVICES
BC CENTRE FOR DISEASE CONTROL
655 WEST 12TH AVENUE, VANCOUVER BC V5Z 4R4
PHONE: (604) 707-2519 | FAX: (604) 707-2515
WWW.BCCDC.CA



- New pages, 31a & 31b, provide information about vaccine safety issues related to influenza vaccine: egg allergy, Oculo-respiratory syndrome, and possibly elevated risk of febrile seizures when trivalent influenza vaccine is given concomitantly with PCV13.
- Pages for vaccines approved for use in Canada, but not part of the BC public campaign have been added as references for community vaccine providers.

Page 44a, Pneumococcal Conjugate Vaccine (Prevnar®13)

- Page reformatted to include a “Precautions” section that provides information on the possibility of an elevated risk of febrile seizures when trivalent influenza vaccine is given concomitantly with PCV13.

Please remove and destroy the following pages from the Communicable Disease Control Manual, Chapter 2 – Immunization Program, Section VII, Biological Products:

TOC, pages 1 & 2	Dated December 2010
Pages 31, 34a, 34b & 34c	Dated September 2010
Pages 32, 33 & 34	Dated October 22, 2010
Page 44a	Dated November 2010

Please insert the following pages in the Communicable Disease Control Manual, Chapter 2 – Immunization Program, Section VII, Biological Products:

TOC pages 1 & 2	Dated September 2011
Pages 31, 31a, 31b, 32, 33, 34, 34 a – 34d & 44a	Dated September 2011

If you have any questions or concerns, please contact Cheryl McIntyre, Clinical Nurse Specialist, at telephone (604) 707-2510, fax (604) 707-2516 or by email at cheryl.mcintyre@bccdc.ca

Sincerely,



Dr. Monika Naus, MD MHS Sc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc: BC Ministry of Health Services:

Dr. Perry Kendall
Provincial Health Officer

Dr. Eric Young
Deputy Provincial Health Officer

Dr. Bob Fisk
Medical Consultant
Non-Communicable Disease

Craig Thompson
Director, CD Prevention – Immunization

Warren O'Briain
Executive Director
Communicable Disease and Addiction Prevention